MediWound (MDWD) stock price, chart and financials

Price chart

Revenue (trailing twelve months)

$11.9M

Revenue (quarter)

$3.1M

Revenue growth (year over year)

−45.83%

Gross profit (trailing twelve months)

$1.8M

Gross margin

15.46%

Net income (trailing twelve months)

−$20.2M

Net income (quarter)

−$7.4M

Net income growth (year over year)

+44.50%

Net margin

−170.10%

Return on equity

−72.37%

EPS (trailing twelve months)

−$1.60

Book value per share

$2.76

P/E (trailing twelve months)

—

Price to book

4.53

Debt to assets

50.41%

Payout ratio

—

Dividend yield

—

Company profile

MediWound Ltd is an integrated biopharmaceutical company focused on developing, manufacturing, and commercializing novel therapeutic products to address unmet medical needs in the fields of severe burns, chronic and other hard-to-heal wounds, connective tissue disorders, and other indications. Its first biopharmaceutical product, NexoBrid, is an FDA-approved orphan biologic for eschar removal in severe burns that can replace surgical interventions and minimize associated costs and complications. Its other product candidates in different stages of the pipeline include EscharEx for debridement of chronic wounds and MW005 for the treatment of non-melanoma skin cancer. The company derives a majority of its revenue from the United States and the rest from the EU and other international markets.

• Is MediWound (MDWD) profitable?

  No. MediWound reported a net loss of $20.2M over the trailing twelve months.

• How much revenue does MediWound (MDWD) make?

  MediWound generated $11.9M in revenue over the trailing twelve months, down 45.83% year over year.

• How do I buy stock in MediWound (MDWD)?

  MDWD trades commission-free with a Light Horse Securities brokerage account — from the mobile app, the web at Light Horse Dashboard, the trading API, or an AI agent connected over MCP. The trade panel on this page places the order once you are signed in.